Compare $ALGS vs $NNVC | Chartloom

Compare

$ALGS vs $NNVC

Aligos Therapeutics Inc · NanoViricides, Inc

ALGS

Aligos Therapeutics Inc

NNVC

NanoViricides, Inc

Compare $ALGS vs $NNVC

Comparing Aligos Therapeutics Inc and NanoViricides, Inc

ALGSAligos Therapeutics Inc

NNVCNanoViricides, Inc

ALGSAligos Therapeutics Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.83x

Rev growth (TTM)

893.0%

YTD performance

-41.5%

52W performance

-46.2%

FCF yield

-286.0%

NNVCNanoViricides, Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

7.4%

52W performance

-9.1%

FCF yield

-23.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALGS

NNVC

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

NNVC

NanoViricides, Inc

Market Cap

ALGS$33M

NNVC$33M

Enterprise Value

ALGS$3M

NNVC$30M

Price

ALGS$5.34

NNVC$1.30

P/E Ratio

ALGSN/A

NNVCN/A

P/S Ratio

ALGS1.05x

NNVC0.00x

EV/Sales

ALGS0.09x

NNVC0.00x

EV/EBITDA

ALGS0.00x

NNVC0.00x

P/B Ratio

ALGS1.09x

NNVC3.76x

P/FCF Ratio

ALGSN/A

NNVCN/A

EV/FCF

ALGS-0.03x

NNVC-3.88x

PEG Ratio

ALGSN/A

NNVCN/A

Forward P/E (NTM)

ALGSN/A

NNVCN/A

Forward P/S (NTM)

ALGS4.83x

NNVCN/A

Revenue (TTM)

ALGS$32M

NNVC$0

Revenue Growth (YoY)

ALGS893.0%

NNVCN/A

Forward Rev Growth

ALGS-84.9%

NNVC0.0%

Gross Margin (TTM)

ALGS0.0%

NNVC0.0%

Operating Margin (TTM)

ALGS0.0%

NNVC0.0%

EBITDA Margin (TTM)

ALGS-247.2%

NNVC0.0%

Net Margin (TTM)

ALGS-241.0%

NNVC0.0%

FCF Margin (TTM)

ALGS-299.9%

NNVCN/A

Net Income (TTM)

ALGS$-76M

NNVC$-8M

FCF (TTM)

ALGS$-95M

NNVC$-8M

EPS (TTM)

ALGS-$7.28

NNVC-$0.37

ROE (TTM)

ALGS-16072.0%

NNVC-9111.0%

ROA (TTM)

ALGS-9230.0%

NNVC-8074.0%

ROIC (TTM)

ALGS-16035.0%

NNVC-9111.0%

Cash

ALGS$30M

NNVC$3M

Debt

ALGS$64K

NNVC$0

Net Cash/Debt

ALGS$30M

NNVC$3M

Current Ratio (TTM)

ALGS2.19x

NNVC2.66x

Quick Ratio (TTM)

ALGS2.19x

NNVC2.35x

Debt/Equity (TTM)

ALGS0.00x

NNVC0.00x

Debt/Assets (TTM)

ALGS0.0%

NNVC0.0%

Interest Coverage (TTM)

ALGSN/A

NNVCN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

NNVC0.00x

Beta

ALGS2.48

NNVC1.91

52W Performance

ALGS-46.2%

NNVC-9.1%

YTD Performance

ALGS-41.5%

NNVC7.4%

% from 52W High

ALGS-61.0%

NNVC-41.7%

% from 52W Low

ALGS34.2%

NNVC52.9%

Asset Turnover (TTM)

ALGS0.38x

NNVC0.00x

FCF Yield (TTM)

ALGS-286.0%

NNVC-23.6%

Earnings Yield (TTM)

ALGS-229.8%

NNVC-24.9%

Dividend Yield (TTM)

ALGSN/A

NNVCN/A

Rule of 40

ALGS593.1

NNVC0.0

EV/GP/RG

ALGSN/A

NNVCN/A

Ticker research

View ALGS research View NNVC research

Metric	ALGS Aligos Therapeutics Inc	NNVC NanoViricides, Inc
Market & Valuation
Market Cap	$33M	$33M
Enterprise Value	$3M	$30M
Price	$5.34	$1.30
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	3.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	-3.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-8M
FCF (TTM)	$-95M	$-8M
EPS (TTM)	-$7.28	-$0.37
ROE (TTM)	-16072.0%	-9111.0%
ROA (TTM)	-9230.0%	-8074.0%
ROIC (TTM)	-16035.0%	-9111.0%
Financial Health
Cash	$30M	$3M
Debt	$64K	$0
Net Cash/Debt	$30M	$3M
Current Ratio (TTM)	2.19x	2.66x
Quick Ratio (TTM)	2.19x	2.35x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	1.91
52W Performance	-46.2%	-9.1%
YTD Performance	-41.5%	7.4%
% from 52W High	-61.0%	-41.7%
% from 52W Low	34.2%	52.9%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-286.0%	-23.6%
Earnings Yield (TTM)	-229.8%	-24.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View NNVC research

Valuation

P/S Ratio

NNVC

0.00x

ALGS

1.05x

EV/FCF

NNVC

-3.88x

ALGS

-0.03x

Growth & revenue

Revenue Growth TTM

ALGS

893.0%

Forward Revenue Growth

NNVC

0.0%

ALGS

-84.9%

Profitability & performance

Gross Margin

ALGS

0.0%

NNVC

0.0%

ROE

NNVC

-9111.0%

ALGS

-16072.0%

FCF Yield %

NNVC

-23.6%

ALGS

-286.0%

52-Week Performance

NNVC

-9.1%

ALGS

-46.2%

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

NNVC

NanoViricides, Inc

Market Cap

ALGS$33M

NNVC$33M

Enterprise Value

ALGS$3M

NNVC$30M

Price

ALGS$5.34

NNVC$1.30

P/E Ratio

ALGSN/A

NNVCN/A

P/S Ratio

ALGS1.05x

NNVC0.00x

EV/Sales

ALGS0.09x

NNVC0.00x

EV/EBITDA

ALGS0.00x

NNVC0.00x

P/B Ratio

ALGS1.09x

NNVC3.76x

P/FCF Ratio

ALGSN/A

NNVCN/A

EV/FCF

ALGS-0.03x

NNVC-3.88x

PEG Ratio

ALGSN/A

NNVCN/A

Forward P/E (NTM)

ALGSN/A

NNVCN/A

Forward P/S (NTM)

ALGS4.83x

NNVCN/A

Revenue (TTM)

ALGS$32M

NNVC$0

Revenue Growth (YoY)

ALGS893.0%

NNVCN/A

Forward Rev Growth

ALGS-84.9%

NNVC0.0%

Gross Margin (TTM)

ALGS0.0%

NNVC0.0%

Operating Margin (TTM)

ALGS0.0%

NNVC0.0%

EBITDA Margin (TTM)

ALGS-247.2%

NNVC0.0%

Net Margin (TTM)

ALGS-241.0%

NNVC0.0%

FCF Margin (TTM)

ALGS-299.9%

NNVCN/A

Net Income (TTM)

ALGS$-76M

NNVC$-8M

FCF (TTM)

ALGS$-95M

NNVC$-8M

EPS (TTM)

ALGS-$7.28

NNVC-$0.37

ROE (TTM)

ALGS-16072.0%

NNVC-9111.0%

ROA (TTM)

ALGS-9230.0%

NNVC-8074.0%

ROIC (TTM)

ALGS-16035.0%

NNVC-9111.0%

Cash

ALGS$30M

NNVC$3M

Debt

ALGS$64K

NNVC$0

Net Cash/Debt

ALGS$30M

NNVC$3M

Current Ratio (TTM)

ALGS2.19x

NNVC2.66x

Quick Ratio (TTM)

ALGS2.19x

NNVC2.35x

Debt/Equity (TTM)

ALGS0.00x

NNVC0.00x

Debt/Assets (TTM)

ALGS0.0%

NNVC0.0%

Interest Coverage (TTM)

ALGSN/A

NNVCN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

NNVC0.00x

Beta

ALGS2.48

NNVC1.91

52W Performance

ALGS-46.2%

NNVC-9.1%

YTD Performance

ALGS-41.5%

NNVC7.4%

% from 52W High

ALGS-61.0%

NNVC-41.7%

% from 52W Low

ALGS34.2%

NNVC52.9%

Asset Turnover (TTM)

ALGS0.38x

NNVC0.00x

FCF Yield (TTM)

ALGS-286.0%

NNVC-23.6%

Earnings Yield (TTM)

ALGS-229.8%

NNVC-24.9%

Dividend Yield (TTM)

ALGSN/A

NNVCN/A

Rule of 40

ALGS593.1

NNVC0.0

EV/GP/RG

ALGSN/A

NNVCN/A

Ticker research

View ALGS research View NNVC research

Metric	ALGS Aligos Therapeutics Inc	NNVC NanoViricides, Inc
Market & Valuation
Market Cap	$33M	$33M
Enterprise Value	$3M	$30M
Price	$5.34	$1.30
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	3.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	-3.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-8M
FCF (TTM)	$-95M	$-8M
EPS (TTM)	-$7.28	-$0.37
ROE (TTM)	-16072.0%	-9111.0%
ROA (TTM)	-9230.0%	-8074.0%
ROIC (TTM)	-16035.0%	-9111.0%
Financial Health
Cash	$30M	$3M
Debt	$64K	$0
Net Cash/Debt	$30M	$3M
Current Ratio (TTM)	2.19x	2.66x
Quick Ratio (TTM)	2.19x	2.35x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	1.91
52W Performance	-46.2%	-9.1%
YTD Performance	-41.5%	7.4%
% from 52W High	-61.0%	-41.7%
% from 52W Low	34.2%	52.9%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-286.0%	-23.6%
Earnings Yield (TTM)	-229.8%	-24.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View NNVC research